Articles tagged with Radiation Therapy
A new accelerated radiotherapy regimen has been shown to improve disease-free survival and locoregional control without increasing late radiation side-effects in patients with head and neck cancer. The six-fraction per week schedule reduces treatment time while maintaining effective tumour control.
A new oral anti-cancer drug, vorinostat, is safe to combine with short-term palliative radiotherapy in patients with advanced pelvic cancer. The therapy may enhance the effect of radiotherapy and could become a component of long-term curative treatment. Patients showed tumor response and reduced side effects when treated with vorinostat.
Researchers at UC Davis Cancer Center found that African-American women with advanced breast cancer have poorer survival rates than white and Hispanic counterparts, regardless of radiation therapy. Despite lower radiation therapy rates, black patients did not benefit from the treatment.
A multi-centre study found that specific lymph node radiotherapy is well-tolerated in early breast cancer patients after mastectomy or breast conserving surgery. The treatment showed no increased toxicity to the heart at three years follow-up, and estimated overall survival rates of 79%.
New research from Karolinska Institutet found that radiotherapy can increase the risk of cardiovascular disease later in life due to sustained inflammation in arteries. The study suggests that post-radiotherapy changes in gene expression may be the cause of this increased risk, which can appear years after treatment.
A phase II study found that stereotactic body radiation therapy (SBRT) effectively eliminated targeted tumors in patients with early-stage inoperable non-small cell lung cancer. The treatment resulted in a 97.6% primary tumor control rate at 3 years, outperforming conventional radiotherapy.
A clinical trial has shown that stereotactic body radiation therapy (SBRT) can eliminate primary tumors in nearly 98% of lung cancer patients. The treatment is fast, convenient and effective, with more than half of patients alive three years after diagnosis.
Stereotactic body radiation therapy (SBRT) shows high rates of primary tumor control and improved survival for patients with inoperable non-small cell lung cancer. The study's findings suggest that SBRT provides more than double the rate of primary tumor control compared to conventional radiotherapy.
The American Society for Radiation Oncology (ASTRO) has awarded travel grants to 17 radiation oncology professionals to attend Advocacy Day. The grants aim to support the financial constraints faced by residents and nurses in advocating for their patients' interests.
A new study published in the Lancet finds that apixaban is more effective and convenient than enoxaparin in preventing thromboembolism after knee replacement surgery. The anticoagulant also poses less risk of bleeding, a concern with current treatments. This could lead to better patient outcomes and quality of life.
A multi-institutional randomized phase III trial analyzed 721 patients with stage III-IV carcinoma of the oral cavity oropharynx hypopharynx or larynx. The study found accelerated radiation therapy reduced chemotherapy toxicity, similar disease-free and local-regional failure rates compared to standard radiation.
Proton beam radiation therapy has been shown to provide encouraging results for patients with locally advanced sinonasal malignancies, with high local control rates at five and eight years after treatment. The study found no significant difference in local control rates based on histological subtype, T stage, or prior surgery.
A new study found that testosterone deficiency after chemotherapy or radiation therapy affects male cancer survivors' quality of life and energy levels. Young male cancer survivors with low testosterone may benefit from replacement therapy.
Research published in Journal of Thoracic Oncology investigates the effectiveness of surgery as a standalone treatment for stage I small cell lung cancer. The study found three- and five-year survival rates of 58.1% and 50.3%, respectively, for patients who underwent lobectomies without radiotherapy.
Research found that split-course palliative radiotherapy reduced patients' symptoms by 52-84% and provided long-lasting relief in 58% of cases. Cancer survival rates were not adversely affected by a two-week break in treatment, demonstrating the regimen's potential as an optimal option for symptom management.
A three-week course of accelerated hypofractionated whole-breast irradiation has been shown to be as safe and effective as the standard five-week regimen for women with early-stage breast cancer. The study, led by Dr. Tim Whelan, found that patients treated with this accelerated therapy had a low risk of side effects and recurrence of ...
A study published in The Lancet Oncology found that hypofractionated radiotherapy schedules do not increase adverse symptoms or worsen body image compared to the international standard treatment. Patients reported moderate or striking concerns about body image, but these did not differ between radiotherapy schedules.
The study analyzed data from 15 trials involving 3,452 women, finding that chemoradiotherapy improved survival rates compared to radiotherapy alone. This treatment also reduced the chance of cancer recurrence and spread.
A non-absorbed oral co-polymer therapy under development by Midway Pharmaceuticals demonstrates ability to protect against radiation damage and prevent lethal bacterial infections in animal models. The compound, PEG 15-20, may provide new way to prevent serious GI side effects of radiation in cancer patients.
A study of 3,754 women found that nearly 50% experience pain symptoms 2-3 years after breast cancer treatment, with young age and supplemental radiation therapy increasing the risk. The most common areas affected by pain are the axilla, arm, breast area, and side of the body.
Adding cetuximab to radiation therapy improves survival rates in patients with locally advanced head and neck cancer, with benefits persisting for up to 5 years. Patients who develop a prominent rash after treatment show significantly improved overall survival compared to those without the rash.
A new study by Henry Ford Hospital found that a patient's socioeconomic status has no effect on their outcome following curative radiation therapy for prostate cancer. The study analyzed data from 788 patients and found that all patients, regardless of race or income, had similar survival rates and biochemical control rates.
A shortened, more intensive course of radiation therapy has been shown to be as effective as traditional treatments for early-stage breast cancers, with no significant side effects. This accelerated hypofractionated whole breast irradiation option is more time-efficient and cost-effective.
A new study suggests that PET imaging before radiation therapy should not be used to determine areas that may benefit from higher doses of radiation. Researchers found that activity patterns in some patients changed completely after treatment, making it unreliable as a predictor.
Researchers at Thomas Jefferson University found that fractionated stereotactic radiotherapy is effective in controlling optic nerve sheath meningioma growth while preserving vision. The treatment resulted in a high rate of stabilized or improved visual acuity, with minimal late complications.
A new study found that a shorter, five-week course of hypofractionated radiation is as effective as standard radiation therapy in reducing prostate cancer recurrence. The treatment delivered higher doses of radiation in fewer sessions, resulting in no significant difference in cancer recurrence or side effects between the two groups.
A study presented at the American Society for Radiation Oncology (ASTRO) found that hypofractionated radiation treatment is more effective in stopping cancer from growing in high-risk prostate cancer patients compared to standard radiation therapy. The new treatment also had no increased risk of negative side effects, making it a valua...
A phase III study found that short-term hormone therapy added to radiation treatment significantly increases survival in medium-risk prostate cancer patients by 51% compared to those receiving radiation alone. In contrast, low-risk patients showed no significant benefit from this combination.
A recent study found that radiation therapy significantly improves regional recurrence control in melanoma patients who underwent lymphadenectomy. The treatment reduced the risk of cancer returning to the lymph nodes by 12 percentage points compared to observation.
A phase III study found that short-term hormone therapy given prior to and during intermediate dose radiation treatment significantly increases the chance of living longer (51 percent) compared to those who receive radiation alone. The benefit appeared to be greatest for men at medium-risk for disease failure.
Researchers found proton therapy to have excellent early tolerance with minimal urinary and rectal toxicity. The study showed a low rate of Grade 3 genitourinary and gastrointestinal side effects, with the most common being minor rectal bleeding.
A study by Fox Chase Cancer Center researchers found that radiation therapy alone can lead to undetectable PSA levels in patients with prostate cancer. Patients with low PSA scores had less chance of biochemical failure and a higher chance of being cured compared to those with detectable PSA levels.
A national clinical trial shows that stereotactic body radiation therapy (SBRT) is effective in treating early-stage lung cancer in patients with unrelated medical comorbidities. The primary lung cancer did not recur 98 percent of the time, and more than half of patients were alive three years after diagnosis.
A study found that adding proton therapy 'boost' to X-ray radiation therapy significantly reduces prostate cancer recurrences in low- and intermediate-risk patients. The high-dose treatment also proves safe with minimal side effects, benefiting these patients with conventional doses of radiation.
Combining chemotherapy with radiotherapy more than doubles event-free survival for patients with locally advanced head and neck cancer without prior surgery. Non-platinum-based chemotherapy shows long-term benefit with lower toxicity compared to platinum therapies.
Research presented at the ASTRO Annual Meeting has shown that short-term hormone therapy added to radiation increases survival for medium-risk prostate cancer patients, while a shorter radiation course is effective in reducing recurrence rates. Additionally, proton therapy reduces recurrences and is well-tolerated in prostate cancer pa...
The world's largest congress on ion therapy brought together leading experts to discuss the latest scientific and clinical developments in radiation therapy. The meeting marked a significant milestone in the technology and clinical application of ion radiation, with over 70,000 patients worldwide treated so far.
The American Society for Radiation Oncology (ASTRO) is partnering with Gilda's Club Chicago to promote cancer survivorship. The two organizations will participate in the Survivor Circle exhibit at ASTRO's 51st Annual Meeting, highlighting programs that help patients and families cope with cancer.
Halos of Hope, a non-profit organization established in 2007, will partner with ASTRO to provide comfort and dignity to chemo patients. The partnership aims to educate members about the organization's mission and programs focused on supporting cancer survivors.
A large study by Mayo Clinic researchers found that patients treated with radiotherapy after prostate cancer surgery experienced very few complications, contradicting concerns about toxicity and side effects. The study suggests that radiation treatment is an effective and safe option for patients with recurrent cancer.
Researchers have identified highly radiosensitive patients who can guide personalized radiotherapy, avoiding severe side effects. The study aims to develop a blood test that can predict patient reaction to radiotherapy, enabling tailored treatment and improved tumour control.
A study found that patients who had surgery before radiation treatment are more likely to complete therapy, while those with other illnesses or chemotherapy are less likely. This highlights the importance of addressing comorbidities and toxic effects of treatment in radiation therapy.
Researchers found that inhibiting NF-kappa B reduced radiation toxicity in zebrafish embryos, offering a potential therapeutic strategy for cancer patients receiving radiation therapy. The study also suggests that downmodulating NF-kappa B activity may be more beneficial than completely ablating it to protect against radiation effects.
Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for prostate cancer have a higher risk of death, according to a study. However, in men without comorbidities, hormone therapy was not associated with an increased risk of all-cause mortality.
Researchers found a strong link between radiotherapy treatment and fatigue, with increases in serum markers of cytokine activity also associated. This study suggests that exposure to radiation releases inflammatory cytokines contributing to fatigue.
Patients who received radiotherapy for low-grade glioma brain tumors showed significant cognitive decline compared to those who did not receive treatment. The study found that attentional functioning, executive functioning, and information processing speed were lower in patients given radiotherapy. Deferring treatment or using modern r...
The American Society for Radiation Oncology has named its 12th class of ASTRO Fellows, recognizing individuals who have made significant contributions to the field of radiation oncology through research, patient care, education, or leadership. The fellows will be recognized at the 51st Annual Meeting in November.
A new trial shows that chemotherapy plus radiotherapy, either with or without surgery, are viable options for patients with stage IIIA (N2) non-small-cell lung cancer. The treatment improved overall survival and progression-free survival rates compared to standard concurrent chemotherapy and radiotherapy alone.
Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke. After a median follow-up of almost 18 years, 96 patients developed cerebrovascular disease, with the incidence rate for stroke being 2.2 times that in the general population. Risk factors include radiation to the neck and mediastinum.
Researchers have developed a new radiotherapy technique that uses real-time images to guide the radiation beam, allowing for more accurate targeting of tumors. This approach promises to reduce damage to healthy tissue and minimize nasty side effects.
A new study from Henry Ford Hospital found that radical prostatectomy significantly increases long-term survival for men under 50 with prostate cancer. The procedure improved cancer-specific and overall survival rates compared to radiotherapy or watchful waiting, making it the recommended treatment option for younger patients.
Researchers are exploring new treatments for lung cancer using targeted therapies and personalized care. Studies have shown promising results in improving patient outcomes, including the use of molecular targeted therapies and chemotherapy combinations.
A new study reveals that lithium promotes DNA repair in irradiated mice, protecting nerves in the hippocampus by decreasing double-strand DNA breaks. Targeted therapies to enhance DNA repair may provide an avenue for future therapeutic development.
Research at the University of Navarra Hospital found that high-dosage perioperative brachytherapy effectively controls 86% of head and neck tumor cases after a seven-year follow-up. The technique reduces treatment time by two weeks compared to conventional radiotherapy, improving patient outcomes.
The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.
A short course of radiation therapy followed by high-quality surgery is the most effective treatment for patients with operable rectal cancer. Recent trials have shown a reduction in local recurrence with radiotherapy and chemotherapy before or after surgery.
A new study finds aggressive surgery followed by targeted radiotherapy is effective in treating a rare form of childhood brain cancer. The treatment improved event-free survival rates, with children under 3 years old showing excellent outcomes.
Researchers investigate thalidomide for biochemical recurrence and adjuvant radiotherapy for improved survival, reducing metastases risk by 29%. Both treatment options show promise for patients with biochemically recurrent prostate cancer after surgery.
Researchers found that fractionated radiation induced an immune imbalance, characterized by elevated expression of pro-inflammatory cytokines, in the distal colonic mucosa. This imbalance persisted even after the end of radiotherapy, with a Th2 profile dominating the immune response.
In a phase III trial, combining endocrine treatment with radiotherapy reduced prostate cancer mortality by half compared to endocrine treatment alone. The study found significant superiority of the combined treatment over hormone therapy alone in reducing prostate cancer-specific mortality and overall survival.